Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients

Abstract

Purpose We compared the efficacy and safety of beinaglutide, a glucagon-like peptide-1 (GLP-1) analogue with metformin in lowering the bodyweight of patients who were overweight/obese and non-diabetic. Patients and Methods Seventy-eight non-diabetic patients were randomly selected and beinaglutide or metformin was administered for 12 weeks. The primary endpoints were changes in body weight and the proportions of patients who lost≥5 and≥10% of their baseline body weights. Results A total of 64 patients completed the study; patients in the beinaglutide group exhibited more bodyweight loss than those in the metformin group [(9.5±0.8%; 9.1±0.9 kg) and (5.1±0.9%; 4.5±0.8 kg), respectively, corresponding to a difference of approximately 4.5 kg (95% confidence interval, 2.2–6.9 kg; P<0.01)]. In the beinaglutide group, 90.6 and 40.6% of the patients lost≥5 and≥10% of their body weight, respectively, whereas, in the metformin group, these rates were 46.9 and 12.5%, respectively (P<0.01 and P<0.05). Weight loss following beinaglutide treatment mainly resulted from the loss of fat mass. Compared to metformin, beinaglutide induced a greater decrease in the body mass index, weight circumference, percent body fat, and body fat mass (total, trunk, limb, android, and gynoid). Additionally, beinaglutide decreased serum insulin levels and ameliorated insulin resistance. Conclusions Beinaglutide is more efficient than metformin at reducing weight and fat mass in patients who are overweight/obese and non-diabetic. Beinaglutide may be a useful therapeutic option for overweight/obesity control in the Chinese population.

Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study

“…12 Treatment exposure was proportional to dose level, with minimal accumulation. 12 These findings, which are consistent with those from previous studies on beinaglutide, 16,17 combined with lifestyle intervention in non-diabetic patients with overweight or obesity. In addition, this trial provided primary findings regarding Chinese patients with a BMI of 24-27.9 kg/m 2 and of 28 kg/m 2 or higher, classified, respectively, as overweight and obese.…”

“…The dosages administered to study participants were carefully balanced to achieve both body weight loss efficacy and tolerability. [14][15][16] The effects of beinaglutide treatment were evaluated in patients with a BMI of 24-27.9 kg/m 2 and of 28 kg/m 2 or higher, respectively, as indicative of overweight and obesity criteria in Chinese guidelines. 19 Beinaglutide was superior to placebo with regard to the two co-primary endpoints; moreover, the mean body weight reduction was sustained during the 12-week post-treatment observation period.…”

“…Although a slight increase in mean body weight occurred at week 28 compared with that at week 16, a significant weight reduction was still evident compared with that at baseline (Figure 1, Table S1). Specifically, beinaglutide resulted in a weight regain rate of 0.78% during the post-treatment observation period from the weight recorded at week 16 weight-reduction targets, beinaglutide-treated patients showed a higher likelihood of achieving a weight reduction of 5% or more and of 10% or more than those administered placebo at week 16 (both P < .0001; Figure 2). This trend continued for all clinically relevant body weight-reduction targets, including reductions of 3% or more, of 5% or more, and of 10% or more, at both week 16 and week 28 (all ORs > 2.5; P < .01 for all comparisons; Figure S3).…”

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

“…This suggests that BN may be an effective treatment for obesity and NASH ( 42 ). A clinical study involving 78 non-diabetic overweight/obese patients found that BN may be a more effective treatment option for overweight/obese Chinese than metformin ( 43 ). For example, a patient with a BMI of 17.96 kg/m 2 found that BN did not make him lose weight but increased it.…”

Pharmacological Treatments and Natural Biocompounds in Weight Management

“…Zhang et al [ 80 ] found that beinaglutide was effective in glycemic control and weight loss in treating type 2 diabetes. Recently, Gao et al [ 81 ] found that beinaglutide was more efficient than metformin at reducing a fat mass in patients of the Chinese population who were overweight and nondiabetic. The effective daily doses of beinaglutide were in the range of 0.24–0.30 mg [ 82 ].…”